{"generic":"Pegademase Bovine","drugs":["Adagen","Pegademase Bovine"],"mono":{"0":{"id":"449955-s-0","title":"Generic Names","mono":"Pegademase Bovine"},"1":{"id":"449955-s-1","title":"Dosing and Indications","sub":{"1":{"id":"449955-s-1-5","title":"Pediatric Dosing","mono":"<ul><li><b>Adenosine deaminase deficiency - Severe combined immunodeficiency disease:<\/b> initial: administer IM every 7 days; 10 units\/kg for first dose, 15 units\/kg for second dose, 20 units\/kg for third dose<\/li><li><b>Adenosine deaminase deficiency - Severe combined immunodeficiency disease:<\/b> maintenance: 20 units\/kg\/wk IM, increase by 5 units\/kg\/wk if necessary; MAX single dose 30 units\/kg<\/li><\/ul>"},"3":{"id":"449955-s-1-7","title":"Indications","mono":"<b>FDA-Labeled Indications<\/b><br\/>Adenosine deaminase deficiency - Severe combined immunodeficiency disease<br\/>"}}},"3":{"id":"449955-s-3","title":"Contraindications\/Warnings","sub":[{"id":"449955-s-3-9","title":"Contraindications","mono":"<ul><li>bone marrow transplantation; lack of evidence supporting safety\/efficacy<\/li><li>severe thrombocytopenia<\/li><\/ul>"},{"id":"449955-s-3-10","title":"Precautions","mono":"<ul><li>Hematologic:<\/li><li>-- mild to moderate thrombocytopenia<\/li><\/ul>"},{"id":"449955-s-3-11","title":"Pregnancy Category","mono":"C (FDA)<br\/>"},{"id":"449955-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"449955-s-4","title":"Drug Interactions","sub":{"1":{"id":"449955-s-4-14","title":"Major","mono":"<ul>Pentostatin (theoretical)<\/ul>"}}},"5":{"id":"449955-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><br\/><b>Dermatologic:<\/b>Injection site pain<br\/><b>Serious<\/b><br\/><b>Hematologic:<\/b>Thrombocytopenia<br\/>"},"6":{"id":"449955-s-6","title":"Drug Name Info","sub":{"0":{"id":"449955-s-6-17","title":"US Trade Names","mono":"Adagen<br\/>"},"2":{"id":"449955-s-6-19","title":"Class","mono":"<ul><li>Enzyme<\/li><li>Immune Stimulant<\/li><\/ul>"},"3":{"id":"449955-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"},"4":{"id":"449955-s-6-21","title":"Generic Availability","mono":"No<br\/>"}}},"7":{"id":"449955-s-7","title":"Mechanism Of Action","mono":"Systemic: In the absence of ADA, accumulation of the purine substrates adenosine and 2'-deoxyadenosine occurs; these substrates and their metabolites are toxic to lymphocytes. Replacement of the ADA results in correction of the metabolic abnormalities, which leads to improvement in immune function, reduced frequency of opportunistic infections, and fewer complications of infections . Pegademase bovine reduces elevated deoxyadenosine triphosphate (dATP) in erythrocytes and increases diminished levels of S-adenosylhomocysteine hydrolase (SAHase) .<br\/>"},"9":{"id":"449955-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>not recommended for IV use<br\/><\/li><li><b>Intramuscular<\/b><br\/>do not dilute<br\/><\/li><\/ul>"},"10":{"id":"449955-s-10","title":"Monitoring","mono":"<ul><li>plasma adenosine deaminase (ADA) activity and red blood cell deoxyadenosine nucleotide (dATP); before treatment<\/li><li>ADA activity: every 1 to 2 weeks during first 8 to 12 weeks of treatment (target, 15 to 35 mcmol\/hr\/mL); twice monthly (between months 3 and 9); then monthly until after 18 to 24 months; and every 2 to 4 months after 2 years of therapy<\/li><li>red blood cell deoxyadenosine nucleotide (dATP) levels: prior to therapy; once level has fallen (0.005 to 0.015 mcmol\/mL or less), 2 to 4 times for remainder of the first year of therapy; 2 to 3 times yearly thereafter; and then twice yearly after 2 years of therapy<\/li><li>assay for antibodies to ADA and pegademase bovine; if level drops below 10 mcmol\/hr\/mL and cannot be accounted for by improper dosing, improper sample handling, or antibody development<\/li><\/ul>"},"11":{"id":"449955-s-11","title":"How Supplied","mono":"<b>Adagen<\/b><br\/>Intramuscular Solution: 250 U\/ML<br\/>"},"13":{"id":"449955-s-13","title":"Clinical Teaching","mono":"<ul><li>This drug may cause headache or injection-site pain.<\/li><li>Advise patient that symptomatic improvement may not be seen for up to 12 months.<\/li><li>Instruct patient to report any signs\/symptoms of thrombocythemia (thrombocytosis) or hemolytic anemia.<\/li><li>Instruct patient to call healthcare professional if a dose is missed, as drug should be given once every seven days.<\/li><\/ul>"}}}